LIVINGSTON, N.J., & WASHINGTON--(BUSINESS WIRE)--A re-analysis of a series of studies of vaginally-administered progesterone versus intramuscular (IM) progesterone injections demonstrates that, when evaluating optimal dosing, clinical results are comparable for early pregnancy support in assisted reproductive technology (ART) cycles, according to data presented today by Paul W. Zarutskie, MD., Zarutskie Fertility and Endocrine Institute, Laguna Niguel, CA. Further, the re-analysis demonstrates that vaginal progesterone is associated with a significantly lower rate of miscarriage than IM progesterone. These data were presented at the American Society for Reproductive Medicine annual meeting in Washington, DC. The re-analysis was supported by a grant from Columbia Laboratories, Inc. (NASDAQ:CBRX).
